NSE: EMCURE · 12 November 2026
- Emcure Pharmaceuticals Ltd. (EMCURE) gained 3.67% during the trading session on November 12, 2026, finishing the day at ₹2,314.40 after moving within a range of ₹2,243.60 and ₹2,344.40.
- Emcure Pharmaceuticals submitted its financial results for the quarter and half-year ended September 30, 2026, reporting operating revenue of ₹28,205 million, marking a 24.30% year-on-year growth. EBITDA expanded by 30.90% to ₹5,748 million with a margin of 20.40%, while profit after tax climbed 29.30% to ₹3,251 million. Growth was propelled by a 12.00% rise in the domestic business alongside a 34.50% surge in international markets.
- Trading volume was 4.06 times the 20-day average daily volume.
Why is Emcure Pharmaceuticals share price rising on 12 November 2026?
Emcure Pharmaceuticals Ltd. (EMCURE) gained 3.67% during the trading session on November 12, 2026, finishing the day at ₹2,314.40 after moving within a range of ₹2,243.60 and ₹2,344.40.
The broader market showed relatively muted movement, with the Nifty benchmark edging up by 0.18%, while the sectoral Nifty Pharma index declined by 0.35%. Emcure's positive performance ran counter to the weak sectoral trend, extending its strong short-term momentum which includes a 5-day return of 8.13% and a 25.01% gain over the past 20 trading sessions.
While no single new corporate announcement was released on November 12, 2026, the stock's continued strength follows its robust financial reporting for the quarter ended September 30, 2026, where the company posted a 24.30% year-on-year rise in operating revenue to ₹28,205 million and a 29.30% increase in profit after tax. Recent corporate actions, including the board's approval for the amalgamation of subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals to streamline the group holding structure, provide broader foundational context for ongoing investor interest.
9.65 lakh shares traded by 12 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.38 lakh shares (4.06 times). The five-day average daily volume was 4.86 lakh shares. Separately, the NSE report for 12 November 2026 showed 5.94 lakh shares delivered, representing 61.60% of that day’s traded volume. The same report recorded 95,872 trades.
The stock advanced 3.67% on significantly elevated volume (4.06x the 20-day average) amid healthy cash delivery participation. While no specific same-day catalyst was disclosed, the move aligns with robust trailing momentum and strong Q2 FY27 financial results reported in early November.
Latest Company Developments
Emcure Pharmaceuticals submitted its financial results for the quarter and half-year ended September 30, 2026, reporting operating revenue of ₹28,205 million, marking a 24.30% year-on-year growth. EBITDA expanded by 30.90% to ₹5,748 million with a margin of 20.40%, while profit after tax climbed 29.30% to ₹3,251 million. Growth was propelled by a 12.00% rise in the domestic business alongside a 34.50% surge in international markets.
Strong quarterly performance and margin expansion validate the company's dual growth strategy across domestic branded generics and international operations.
The Board of Directors approved a scheme of amalgamation for wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company Emcure Pharmaceuticals Limited. The proposed restructuring remains subject to requisite statutory and regulatory approvals. Management noted the move supports the 'One Emcure' vision to simplify the group holding structure and unlock operational synergies.
Corporate restructuring simplifies the corporate hierarchy and enhances backend and operational efficiencies across the group.
The company disclosed the receipt of various orders from the Income-tax Department imposing an aggregate penalty of ₹57,73,96,732 across financial years spanning from 2014-15 to 2020-21. Emcure stated it is evaluating appropriate legal remedies, including filing appeals before the relevant Appellate Authority.
Tax penalty assessments introduce regulatory and legal contingencies that require ongoing monitoring regarding potential financial outflows.
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Emcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries with Emcure Pharmaceuticals Limited – Holding Company, subject to requisite statutory and regulatory approvals.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 7.05% on 30 September 2026. This compares with 6.87% on 30 June 2026, a change of +0.18 percentage points.
The filing reported 23 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and regulatory progress regarding the proposed amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals.
- Developments regarding the income tax penalty assessment appeals and legal proceedings.
- Growth trajectory in key domestic chronic therapy segments such as women's health, cardio-metabolics, and CNS.
- Scaling of international portfolios across Europe, Canada, and Rest of World markets.
Other Dated Coverage
- Emcure Pharmaceuticals Share Price Today: Rises 17.60% in 5 Trading Sessions | 9 November 2026 — 9 November 2026
- Emcure Pharmaceuticals Share Price Today: Rises 11.95% in 3 Trading Sessions | 6 November 2026 — 6 November 2026
- Emcure Pharmaceuticals Share Price Today: Rises 15.43% in 2 Trading Sessions | 4 November 2026 — 4 November 2026
More Emcure Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Emcure Pharmaceuticals company news?
Emcure Pharmaceuticals submitted its financial results for the quarter and half-year ended September 30, 2026, reporting operating revenue of ₹28,205 million, marking a 24.30% year-on-year growth. EBITDA expanded by 30.90% to ₹5,748 million with a margin of 20.40%, while profit after tax climbed 29.30% to ₹3,251 million. Growth was propelled by a 12.00% rise in the domestic business alongside a 34.50% surge in international markets.
How strong was Emcure Pharmaceuticals’s trading volume?
9.65 lakh shares traded, 4.06 times the 20-day average daily volume. The price and volume data are dated 12 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.